{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:44:15Z","timestamp":1792601055100,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clinthera.2026.02.010","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:40:54Z","timestamp":1773952854000},"page":"347-384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"48","author":[{"given":"Ishraq","family":"Choudhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Headly","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahana","family":"Mahesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazli","family":"Azmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Anson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.02.010_bib0001","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2337\/dc23-0177","article-title":"Severe Mental Illness and Type 2 Diabetes Outcomes and Complications: A Nationwide Cohort Study","volume":"46","author":"Fleetwood","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.19132","article-title":"Diabetes and Its Association With Psychiatric Disorders in Young Adults in South Korea","volume":"6","author":"Lee","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/gpsych-2019-100076","article-title":"More anxious than depressed: prevalence and correlates in a 15-nation study of anxiety disorders in people with type 2 diabetes mellitus","volume":"32","author":"Chaturvedi","year":"2019","journal-title":"Gen Psychiatr"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pcd.2021.11.001","article-title":"A systematic review and meta-analysis to compare the prevalence of depression between people with and without Type 1 and Type 2 diabetes","volume":"16","author":"Farooqi","year":"2022","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0005","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00592-020-01648-9","article-title":"The prevalence of mild cognitive impairment in type 2 diabetes mellitus patients: a systematic review and meta-analysis","volume":"58","author":"You","year":"2021","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0006","doi-asserted-by":"crossref","first-page":"100,135","DOI":"10.1016\/j.dscb.2024.100135","article-title":"The impact of diabetes mellitus on the development of psychiatric and neurological disorders","volume":"14","author":"Kelly","year":"2024","journal-title":"Brain Disord"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0007","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/mds.29122","article-title":"The Impact of Type 2 Diabetes in Parkinson\u2019s Disease","volume":"37","author":"Athauda","year":"2022","journal-title":"Movement Disorders"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0008","doi-asserted-by":"crossref","first-page":"e3673","DOI":"10.1002\/dmrr.3673","article-title":"Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta-analysis","volume":"39","author":"Tian","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0009","doi-asserted-by":"crossref","first-page":"102,834","DOI":"10.1016\/j.arr.2025.102834","article-title":"Effects of antidiabetic medications on the relationship between type 2 diabetes mellitus and cognitive impairment","volume":"112","author":"Cozza","year":"2025","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0010","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0011","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0012","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.bbadis.2013.01.008","article-title":"Crosstalk between diabetes and brain: Glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration","volume":"1832","author":"Duarte","year":"2013","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0013","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.3390\/ijms26115338","article-title":"GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives","volume":"26","author":"Marquez-Meneses","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0014","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and Mental Health","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0015","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s44220-025-00390-x","article-title":"An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders","volume":"3","author":"De Giorgi","year":"2025","journal-title":"Nature Mental Health"},{"issue":"1","key":"10.1016\/j.clinthera.2026.02.010_bib0016","first-page":"330,936","article-title":"Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"15","author":"Chen","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0017","doi-asserted-by":"crossref","first-page":"102,726","DOI":"10.1016\/j.eclinm.2024.102726","article-title":"12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study","volume":"74","author":"De Giorgi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0018","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson\u2019s disease: a cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0019","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40618-024-02466-4","article-title":"Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network","volume":"48","author":"Nassar","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0020","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/mds.29992","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson\u2019s Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study","volume":"39","author":"Tang","year":"2024","journal-title":"Movement Disorders"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0021","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70075","article-title":"GLP-1 Agonists as Potential Neuromodulators in Development of Parkinson\u2019s Disease: A Nationwide Cohort Study","volume":"32","author":"Gamborg","year":"2025","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0022","doi-asserted-by":"crossref","first-page":"107,132","DOI":"10.1016\/j.parkreldis.2024.107132","article-title":"Anti-diabetic drug use and reduced risk of Parkinson\u2019s disease: A community-based cohort study","volume":"128","author":"Rozani","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0023","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jamainternmed.2024.4346","article-title":"Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology","volume":"184","author":"Wadden","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0024","doi-asserted-by":"crossref","first-page":"113,537","DOI":"10.1016\/j.intimp.2024.113537","article-title":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study","volume":"143","author":"Siddeeque","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0025","doi-asserted-by":"crossref","first-page":"111,128","DOI":"10.1016\/j.pnpbp.2024.111128","article-title":"Movement disorders related to antidiabetic medications: a real-world pharmacovigilance study","volume":"135","author":"Zhao","year":"2024","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0026","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/pds.5448","article-title":"Association between different diabetes medication classes and risk of <scp>Parkinson<\/scp>\u2019s disease in people with diabetes","volume":"31","author":"Sunnarborg","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0027","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson\u2019s Disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0028","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0029","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0030","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of Lixisenatide in Early Parkinson\u2019s Disease","volume":"390","author":"Meissner","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0031","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0032","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-Weekly Semaglutide in Adults With Alcohol Use Disorder","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0033","doi-asserted-by":"crossref","first-page":"32,385","DOI":"10.1038\/s41598-025-17927-w","article-title":"A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity","volume":"15","author":"Quddos","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0034","doi-asserted-by":"crossref","first-page":"108,614","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0035","doi-asserted-by":"crossref","first-page":"102,429","DOI":"10.1016\/j.eclinm.2024.102429","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial","volume":"68","author":"L\u00fcthi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0036","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study","volume":"29","author":"Wang","year":"2024","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0037","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0038","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jad.2024.10.062","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase\u00ae)","volume":"369","author":"McIntyre","year":"2025","journal-title":"J Affect Disord"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080679","article-title":"Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study","volume":"388","author":"Shapiro","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","article-title":"Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0041","unstructured":"Barbulescu A, Restrepo-M\u00e9ndez MC, Flynn R. Association between exposure to GLP-1 receptor agonists and risk of suicide-related and self-harm-related events \u2013 including post-hoc analysis. European Medicines Agency. Accessed online : https:\/\/catalogues.ema.europa.eu\/system\/files\/2024-04\/Final%20study%20report_Suicidal%20ideation%20and%20GLP1.pdf. 2024."},{"key":"10.1016\/j.clinthera.2026.02.010_bib0042","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1111\/dom.15864","article-title":"Association between <scp>glucagon-like peptide<\/scp>-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database","volume":"26","author":"Kim","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0043","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1192\/j.eurpsy.2023.2474","article-title":"Postmarket safety profile of suicide\/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis","volume":"66","author":"Chen","year":"2023","journal-title":"European Psychiatry"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0044","doi-asserted-by":"crossref","first-page":"103,029","DOI":"10.1016\/j.eclinm.2024.103029","article-title":"Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study","volume":"80","author":"Bezin","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0045","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1192\/j.eurpsy.2024.1803","article-title":"Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database","volume":"68","author":"Lu","year":"2025","journal-title":"European Psychiatry"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0046","article-title":"Risk of suicide, hair loss, and aspiration with GLP1-receptor agonists and other diabetic agents: a real-world pharmacovigilance study","author":"Nakhla","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0047","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.23385","article-title":"Disproportionality analysis from World Health Organization data on semaglutide, liraglutide, and suicidality","volume":"7","author":"Schoretsanitis","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0048","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jdiacomp.2011.03.002","article-title":"Psychological and quality of life changes in patients using GLP-1 analogues","volume":"25","author":"Grant","year":"2011","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0049","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1111\/dom.15616","article-title":"Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants","volume":"26","author":"Almeida","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0050","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.pcd.2024.05.005","article-title":"Glucagon-like peptide receptor agonists and risk for depression","volume":"18","author":"Tagliapietra","year":"2024","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0051","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023830","article-title":"Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink","volume":"8","author":"Gamble","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0052","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.pcd.2015.06.003","article-title":"Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study","volume":"10","author":"Moulton","year":"2016","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0053","doi-asserted-by":"crossref","first-page":"112,167","DOI":"10.1016\/j.diabres.2025.112167","article-title":"Association of antidiabetic medications with depression risk and All-Cause mortality in type 2 Diabetes: A TriNetX-Based cohort study","volume":"223","author":"Chen","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0054","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/osp4.619","article-title":"A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder","volume":"9","author":"Allison","year":"2023","journal-title":"Obes Sci Pract"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0055","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/oby.22653","article-title":"Effects of liraglutide and behavioral weight loss on food cravings, eating behaviors, and eating disorder psychopathology","volume":"27","author":"Chao","year":"2019","journal-title":"Obesity"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0056","doi-asserted-by":"crossref","first-page":"100,080","DOI":"10.1016\/j.obpill.2023.100080","article-title":"Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study","volume":"7","author":"Richards","year":"2023","journal-title":"Obesity Pillars"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0057","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.dsx.2020.03.009","article-title":"Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study","volume":"14","author":"Da Porto","year":"2020","journal-title":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0058","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2337\/dc21-2064","article-title":"Enhancement of impaired olfactory neural activation and cognitive capacity by liraglutide, but not dapagliflozin or acarbose, in patients with type 2 diabetes: a 16-week randomized parallel comparative study","volume":"45","author":"Cheng","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0059","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","article-title":"Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study","volume":"207","author":"Mansur","year":"2017","journal-title":"J Affect Disord"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0060","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.7326\/M23-3220","article-title":"Sodium\u2013glucose cotransporter-2 inhibitors, dulaglutide, and risk for dementia","volume":"177","author":"Hong","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0061","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020734","article-title":"Activation of glucagon-like peptide-1 receptor ameliorates cognitive decline in type 2 diabetes mellitus through a metabolism-independent pathway","volume":"10","author":"Li","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0062","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.2337\/dc18-2584","article-title":"Olfactory dysfunction mediates adiposity in cognitive impairment of type 2 diabetes: insights from clinical and functional neuroimaging studies","volume":"42","author":"Zhang","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0063","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s40618-024-02320-7","article-title":"Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial","volume":"47","author":"Dei Cas","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0064","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40618-024-02466-4","article-title":"Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network","volume":"48","author":"Nassar","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0065","doi-asserted-by":"crossref","first-page":"101,623","DOI":"10.1016\/j.diabet.2025.101623","article-title":"Comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in preventing Alzheimer\u2019s disease, vascular dementia, and other dementia types among patients with type 2 diabetes","volume":"51","author":"Sun","year":"2025","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0066","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0067","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/13872877251351329","article-title":"Associations of semaglutide with Alzheimer\u2019s disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study","volume":"106","author":"Wang","year":"2025","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0068","doi-asserted-by":"crossref","first-page":"102,689","DOI":"10.1016\/j.eclinm.2024.102689","article-title":"Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study","volume":"73","author":"Tang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0069","doi-asserted-by":"crossref","DOI":"10.1177\/1533317519899546","article-title":"Antidiabetic drugs for the risk of alzheimer disease in patients with type 2 DM using FAERS","volume":"35","author":"Akimoto","year":"2020","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0070","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1007\/s00415-024-12300-9","article-title":"Comparing major and mild cognitive impairment risks in older type-2 diabetic patients: a Danish register-based study on dipeptidyl peptidase-4 inhibitors vs. glucagon-like peptide-1 analogues","volume":"271","author":"Battini","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0071","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.70058","article-title":"Impact of glucagon-like peptide-1 receptor agonists on the dementia incidence in patients with type 2 diabetes mellitus: a population-based longitudinal cohort study","volume":"41","author":"Cheng","year":"2025","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0072","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/dom.16046","article-title":"Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the <scp>SURMOUNT<\/scp>-1 study","volume":"27","author":"Gudzune","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0073","doi-asserted-by":"crossref","first-page":"101,865","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0074","doi-asserted-by":"crossref","first-page":"109,946","DOI":"10.1016\/j.neuropharm.2024.109946","article-title":"GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice","volume":"252","author":"Liu","year":"2024","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.clinthera.2026.02.010_bib0075","first-page":"462,240","article-title":"Neuroprotective effects of GLP-1 class drugs in Parkinson\u2019s disease","volume":"15","author":"Lv","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0076","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0077","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/bmj.318.7179.311","article-title":"Science, medicine, and the future: Parkinson\u2019s disease","volume":"318","author":"Schapira","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0078","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FBP.0000000000000609","article-title":"Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats","volume":"32","author":"Douton","year":"2021","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0079","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00001756-199702100-00014","article-title":"Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra","volume":"8","author":"French","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0080","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3390\/medsci13030136","article-title":"Mechanisms of GLP-1 in modulating craving and addiction: neurobiological and translational insights","volume":"13","author":"Amorim Moreira Alves","year":"2025","journal-title":"Medical Sciences"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0081","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40473-019-0170-4","article-title":"Current understanding of the neurobiology of opioid use disorder: an overview","volume":"6","author":"Moningka","year":"2019","journal-title":"Curr Behav Neurosci Rep"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0082","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.3390\/ijms26115338","article-title":"GLP-1 analogues in the neurobiology of addiction: translational insights and therapeutic perspectives","volume":"26","author":"Marquez-Meneses","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0083","doi-asserted-by":"crossref","first-page":"109,946","DOI":"10.1016\/j.neuropharm.2024.109946","article-title":"GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice","volume":"252","author":"Liu","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0084","doi-asserted-by":"crossref","first-page":"114,187","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0085","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.2337\/db17-1385","article-title":"Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons","volume":"67","author":"Adams","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0086","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40035-024-00431-y","article-title":"SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system","volume":"13","author":"Mei","year":"2024","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0087","doi-asserted-by":"crossref","first-page":"970,925","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: An in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0088","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0089","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ntr\/ntaf005","article-title":"Exploring predictors of treatment response to GLP-1 receptor agonists for smoking cessation","volume":"27","author":"Yammine","year":"2025","journal-title":"Nicotine and Tobacco Research"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0090","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0091","article-title":"Association between exenatide use and incidence of Alzheimer\u2019s disease","volume":"7","author":"Zhou","year":"2021","journal-title":"Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0092","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial","volume":"19","author":"Cukierman-Yaffe","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0093","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/acps.12711","article-title":"No cognitive-enhancing effect of <scp>GLP<\/scp>-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia","volume":"136","author":"Ish\u00f8y","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0094","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/oby.24222","article-title":"Safety profile of semaglutide versus placebo in the <scp>SELECT<\/scp>study: a randomized controlled trial","volume":"33","author":"Kushner","year":"2025","journal-title":"Obesity"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0095","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1007\/s00125-024-06243-z","article-title":"Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study","volume":"67","author":"Hurtado","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0096","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.clinthera.2026.02.010_bib0097","doi-asserted-by":"crossref","first-page":"102,777","DOI":"10.1016\/j.eclinm.2024.102777","article-title":"Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study","volume":"75","author":"Anson","year":"2024","journal-title":"EClinicalMedicine"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:36:43Z","timestamp":1776436603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826000445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0149291826000445"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.02.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}